Phase 3 Readout

CGC: Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva

Name: Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva
Start: 2026-11-01
End: 2026-11-01

November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 1, 2026
Company: Canopy Growth Corp (CGC)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva

November 1, 2026

CGC overview →

Company: Canopy Growth Corp (CGC)
Indication: Primary Immune Deficiency